180 related articles for article (PubMed ID: 32914879)
1. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Geller JI; Pressey JG; Smith MA; Kudgus RA; Cajaiba M; Reid JM; Hall D; Barkauskas DA; Voss SD; Cho SY; Berg SL; Dome JS; Fox E; Weigel BJ
Cancer; 2020 Dec; 126(24):5303-5310. PubMed ID: 32914879
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
[TBL] [Abstract][Full Text] [Related]
3. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
Wood AC; Maris JM; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Wu J; Kurmasheva RT; Whiteman K; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Nov; 60(11):1860-7. PubMed ID: 23798344
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.
Ailawadhi S; Kelly KR; Vescio RA; Jagannath S; Wolf J; Gharibo M; Sher T; Bojanini L; Kirby M; Chanan-Khan A
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):29-34. PubMed ID: 30340993
[TBL] [Abstract][Full Text] [Related]
5. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.
Berdeja JG
Front Biosci (Landmark Ed); 2014 Jan; 19(1):163-70. PubMed ID: 24389179
[TBL] [Abstract][Full Text] [Related]
6. Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis.
Yap LW; Brok J; Pritchard-Jones K
Fetal Pediatr Pathol; 2017 Feb; 36(1):62-75. PubMed ID: 27935326
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
[TBL] [Abstract][Full Text] [Related]
8. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
[TBL] [Abstract][Full Text] [Related]
14. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Tolcher AW; Ochoa L; Hammond LA; Patnaik A; Edwards T; Takimoto C; Smith L; de Bono J; Schwartz G; Mays T; Jonak ZL; Johnson R; DeWitte M; Martino H; Audette C; Maes K; Chari RV; Lambert JM; Rowinsky EK
J Clin Oncol; 2003 Jan; 21(2):211-22. PubMed ID: 12525512
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Hensley ML; Hirst CM; Ezeoke MO; Ahn L; Qin LX; Antonescu CR; Lefkowitz RA; Maki RG; Schwartz GK; Tap WD
Oncologist; 2019 Jun; 24(6):857-863. PubMed ID: 30126857
[TBL] [Abstract][Full Text] [Related]
17. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
Adamson PC; Matthay KK; O'Brien M; Reaman GH; Sato JK; Balis FM
Pediatr Blood Cancer; 2007 Oct; 49(5):661-5. PubMed ID: 16900483
[TBL] [Abstract][Full Text] [Related]
19. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
